

COMPOSITION

Each enteric coated tablet contains 325 mg Pancreatin BP (Each gram of pancreatin contains 1400 FIP units of protease activity, 20000 FIP units of lipase activity and 24000 FIP units of amylase activity).

PHARMACOLOGY

Suzyme^e is a preparation of Pancreatin having protease, lipase and amylase enzyme activity. Pancreatin hydrolyses fats to glycerol and fatty acids, changes protein into proteoses and derived substances and converts starch into dextrins and sugars. Pancreatin is employed in the conditions where the secretion of pancreatic juice is deficient.

INDICATION

Children:

- Reduced or absence of pancreatic exocrine secretion
- Cystic fibrosis

Adults:

In the conditions with deficient pancreatic exocrine function such as -Following pancreatectomy -Following total gastrectomy

- -Chronic pancreatitis
- -Steatorrhea
- -Steatormea -Somatostatinoma
- -Somatostatinoma -Celiac disease
- -Cellac disease

DOSAGE AND ADMINISTRATION

1-3 tablets daily with meal or as per direction of the physician.

ADVERSE REACTION

Pancreatin may cause buccal and perianal soreness, particularly in infants. Hypersensitivity reactions have been reported; these may be sneezing, lacrimation or skin rashes.

DRUG INTERACTIONS

Alkaline media will rupture the enteric coating. As such to prevent bursting out of the content in the stomach Pancreatin should not be used concurrently with antacid.

OVERDOSAGE

Excessive dosage may produce a laxative effect. Systemic toxicity does not occur. Very high dosage may cause hyperuricemia and hyperuricosuria.

PRECAUTION

A proper balance between fat, protein and starch intake must be maintained to avoid temporary indigestion.

PREGNANCY AND LACTATION

Pregnancy category C. Not known whether Pancreatin is distributed into milk. Caution advised if Pancreatin is used.

STORAGE

Store in a cool and dry place. Keep out of the reach of children.

HOW SUPPLIED

Suzyme® tablet: Box containing 100 tablets in strip pack.

